Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women

Journal of Medical Virology

Volumn 85, Issue 10, 2013, Pages 1786-1793

  Tong, Yan ^a   Ermel, Aaron ^a   Tu, Wanzhu ^a   Shew, Marcia ^a   Brown, Darron R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent women; Antibody response; Human papillomavirus

Indexed keywords

HEMOGLOBIN BETA CHAIN; NEUTRALIZING ANTIBODY; VIRUS DNA;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; DNA ISOLATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOASSAY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; VAGINA SMEAR; VIRUS DETECTION; VIRUS LOAD;

ADOLESCENT WOMEN; ANTIBODY RESPONSE; HUMAN PAPILLOMAVIRUS;

ADOLESCENT; ANTIBODIES, VIRAL; DNA, VIRAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES; VAGINA;

HUMAN PAPILLOMAVIRUS;

EID: 84881027793     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23664     Document Type: Article

References (34)

1. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, Juliar BE, Breen TE, Fortenberry JD. 2005. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191:182-192.
2. Brown CR, Leon ML, Munoz K, Fagioni A, Amador LG, Frain B, Tu W, Qadadri B, Brown DR. 2009. Human papillomavirus infection and its association with cervical dysplasia in Ecuadorian women attending a private cancer screening clinic. Braz J Med Biol Res 42:629-636.
3. Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, Radley D, Vuocolo S, Garner EI, Haupt RM, Bryan JT. 2011. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccine 7:230-238.
4. Castle PE, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG, Scott DR, Sherman ME, Schiffman M. 2002. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis 29:182-187.
5. Clifford GM, Shin HR, Oh JK, Waterboer T, Ju YH, Vaccarella S, Quint W, Pawlita M, Franceschi S. 2007. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 16:1874-1879.
6. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT. 2005. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11 16, and 18. Clin Diagn Lab Immunol 12:959-969.
7. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D. 2009. Clinician's guide to human papillomavirus immunology: Knowns and unknowns. Lancet Infect Dis 9:347-356.
8. Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR. 2009. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 51:274-282.
9. Gravitt PE. 2011. The known unknowns of HPV natural history. J Clin Invest 121:4593-4599.
10. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. 2000. Improved amplification of genital human papillomaviruses. J Clin Microbiol 38:357-361.
11. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. New Engl J Med 338:423-428.
12. Ho GY, Studentsov YY, Bierman R, Burk RD. 2004. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13:110-116.
13. Malik ZA, Hailpern SM, Burk RD. 2009. Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 22:445-449.
14. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T, Crowley-Nowick PA, Levin L, Wilson CM. 2000. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: Impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 154:127-134.
15. Nonnenmacher B, Kruger Kjaer S, Svare EI, Scott JD, Hubbert NL, van den Brule AJ, Kirnbauer R, Walboomers JM, Lowy DR, Schiller JT. 1996. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations. Int J Cancer 68:704-709.
16. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11 16, and 18 by a multiplexed Luminex assay. Clinical Diagnostic Lab Immunol 10:108-115.
17. Porras C, Bennett C, Safaeian M, Coseo S, Rodriguez AC, Gonzalez P, Hutchinson M, Jimenez S, Sherman ME, Wacholder S, Solomon D, van Doorn LJ, Bougelet C, Quint W, Schiffman M, Herrero R, Hildesheim A. 2010. Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis 10:238.
18. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A. 2010. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 102:1653-1662.
19. Shew ML, Fortenberry JD, Tu W, Juliar BE, Batteiger BE, Qadadri B, Brown DR. 2006. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 160:151-156.
20. Silins I, Kallings I, Dillner J. 2000. Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 9:953-959.
21. Stanley M. 2006. Immune responses to human papillomavirus. Vaccine (Supp.1): S16-S22.
22. Stanley MA. 2012. Epithelial cell responses to infection with human papillomavirus. Clinical Microbiol Rev 25:215-222.
23. Tarkowski TA, Koumans EH, Sawyer M, Pierce A, Black CM, Papp JR, Markowitz L, Unger ER. 2004. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 189:46-50.
24. Trottier H, Franco EL. 2006. The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl 1):S1-S15.
25. Tu W, Batteiger BB, Wiehe S, Ofner S, Van Der Pol B, Katz BP, Orr DP, Fortenberry JD. 2009. Time from first intercourse to first sexually transmitted infection among adolescent women. Arch Pediatr Adolesc Med 163:1106-1111.
26. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278.
27. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Sherman ME, Wang S, Clayman B, Burk RD. 2004. Seroreactivity to human papillomavirus (HPV) types 16, 18 or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13:324-327.
28. Wang SS, Schiffman M, Herrero R, Carreon J, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Clayman B, Burk RD, Viscidi RP. 2004. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 91:1269-1274.
29. Weaver B, Shew M, Qadadri B, Tu W, Tong Y, Denski C, Fortenberry JD, Brown D. 2011. Natural history of multiple human papillomavirus infections in female adolescents with prolonged follow-up. J Adolesc Health 48:473-480.
30. Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, Morales J, Wacholder S, Guillen D, Alfaro M, Safaeian M, Burk RD, Schiffman M. 2011. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 204:94-102.
31. Wideroff L, Schiffman MH, Hoover R, Tarone RE, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, Lörincz AT, Manos MM, Glass AG, Scott DR, Sherman ME, Buckland J, Lowy D, Schiller J. 1996. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV16 DNA-positive and negative women. J Infect Dis 174:937-943.
32. Winer RL, Harris TG, Xi LF, Jansen KU, Hughes JP, Feng Q, Welebob C, Ho J, Lee SK, Carter JJ, Galloway DA, Kiviat NB, Koutsky LA. 2009. Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol 81:713-721.
33. Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O'Reilly S, Kiviat NB, Koutsky LA. 2011. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20:699-707.
34. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. 2001. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357:1831-1836.